StapleBio develops nucleic acid medicines using its proprietary Staple nucleic acid technology, which selectively binds to target mRNA and alters its structure to modulate protein expression levels. This approach enables the rapid development of treatments for rare diseases, viral infections, and other conditions that have been difficult to address with traditional therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, including rare genetic disorders and viral infections, are difficult to treat with conventional therapies due to challenges in modulating protein expression levels with high precision and minimal off-target effects. Traditional drug development approaches often struggle to address these conditions effectively.
Solution
StapleBio is developing a new class of nucleic acid medicines based on its proprietary Staple nucleic acid technology. This technology enables selective binding to target mRNA, altering its structure to precisely modulate protein expression levels. By either increasing or decreasing protein production, StapleBio's approach offers a versatile platform for therapeutic intervention. The technology's unique mechanism of action allows for the rapid development of treatments for previously intractable diseases.
Target Audience
The primary target audience includes patients suffering from rare diseases and viral infections, as well as pharmaceutical companies seeking novel therapeutic modalities.
Features
- Staple nucleic acids selectively bind to target RNA sequences.
- Modulates RNA structure to control protein expression levels.
- Can either increase or decrease protein production, depending on the therapeutic goal.
- Demonstrates high target specificity, reducing off-target effects.
- Exhibits excellent stability within biological systems.
- Allows for rapid functional validation and drug development.